Aimovig® receives positive CHMP opinion for the prevention of migraine

Written by Sharon Salt, Editor

Novartis (Frimley, UK) have announced that they have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the use of Aimovig® (erenumab) for the prevention of migraine in adult patients who experience more than 4 migraine days per month. If Aimovig is approved, then it will be the first and only preventive treatment designed specifically to block the calcitonin gene-related peptide (CGRP) receptor which is thought to be responsible for transmitting pain signals associated with migraine.  Discover more on the approval stages of Aimovig in our news coverages below: June 2017: Monoclonal antibody could...

To view this content, please register now for access

It's completely free